In the field of medicine, the treatment of central nervous system (CNS) diseases has always been a major challenge for scientists and clinicians. According to the prediction of the World Health Organization (WHO), CNS diseases are predicted to become the second leading cause of mortality on a global scale in the next 20 years, subsequent to cardiovascular disease. This has not only revealed the increasingly severe situation of CNS diseases, but also underscored the pressing need for the R&D of novel and effective therapeutic drugs. Globally, despite the deep involvement of major transnational pharmaceutical companies such as Eli Lilly and Johnson & Johnson in this field for many years, the success rate of R&D of CNS drugs is significantly lower than those in other therapeutic areas, only around 6%. Behind this figure are multiple challenges such as complex pathogenesis, difficult breakthrough of blood-brain barrier, and dual consideration of therapeutic effect and safety.
However, it is against this background that China's R&D of new drugs for CNSquietly shows strong competitiveness and a broad development prospects. In recent years, bolstered by advancements in domestic research capabilities, optimized policy environments, and enhanced corporate innovation, China has gradually shifted from a follower to a competitor in CNS new drug development, even taking the lead in certain areas. This article aims to explore the current state, challenges, and opportunities in the development of CNS new drugs in China while analyzing future growth trends.
From "Old Drugs Dominating" to "New Drug Emergence"
For a long time, the CNS treatment market in China has been dominated by original drugs of foreign companies and their generics, especially in the field of anti-depression and anti-psychotics, where classic old drugs such as fluoxetine and venlafaxine have long been dominated the top. Although old drugs have to some extent relieved patients' symptoms, their limitations such as singular mechanism of action and obvious side effects make it difficult to meet the diverse needs in clinical practice. Therefore, it has become a consensus in the pharmaceutical industry to develop novel, efficient, and safe new drugs for CNS.
In recent years, China's pharmaceutical companies have made significant breakthroughs in this field. Taking Luye Pharma as an example, the company's self-developed anti-depression class 1 innovative drug Ruoxinlin (Toludesvenlafaxine Hydrochloride Extended-Release Tablets) was successfully launched in early 2023, marking the emergence of the first original drug for the anti-depression that is self-developed and possesses independent intellectual property right. Ruoxinlin, as an innovative triple reuptake inhibitor, has shown comprehensive and stable therapeutic effect for depression. It can not only significantly relieve the anxiety of patients, but also effectively improve symptoms such as emotional blocking, fatigue, and anhedonia, as well as enhance cognitive abilities of patients. Of particular significance is that Ruoxinlin has shown good safety and tolerability in clinical practice, providing patients with a more comfortable treatment experience. The marketing of this innovative drug not only broke the monopoly of original drugs of foreign companies in the field of CNS, but also set a new benchmark for China's R&D of new drugs for CNS.
In addition to Ruoxinlin, Luye Pharma has also strategically developed a variety of new drugs such as RYKINDO (risperidone microspheres injection) for schizophrenia and ERZOFRI (paliperidone palmitate sustained release suspension injection) in the field of CNS, which have been approved for marketing at home and abroad, and shown good clinical efficacy and market prospects. Furthermore, Luye Pharma has also developed a series of product portfolio including Jinyouping (rotigotine microspheres for injection), etc., targeting diseases with large number of unmet needs such as Parkinson's disease and Alzheimer's disease. The R&D and marketing of these new drugs has enriched CNS treatment market in China, and provided more therapeutic options for global patients a...
(All Rights Reserved)